Assuntos
Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Clozapina/efeitos adversos , Diabetes Mellitus Tipo 2/induzido quimicamente , Diabetes Mellitus Tipo 2/tratamento farmacológico , Pirenzepina/análogos & derivados , Pirenzepina/uso terapêutico , Adulto , Antipsicóticos/administração & dosagem , Benzodiazepinas , Clozapina/uso terapêutico , Diabetes Mellitus Tipo 2/prevenção & controle , Esquema de Medicação , Humanos , Masculino , Olanzapina , Cooperação do Paciente , Pirenzepina/administração & dosagem , Qualidade de Vida , Esquizofrenia Paranoide/tratamento farmacológicoRESUMO
The objective of this study was to evaluate the efficacy and safety of olanzapine in patients with schizophrenia and comorbid substance abuse disorders. Thirty patients who met DSM-IV criteria for schizophrenia or schizoaffective disorder as well as criteria for substance abuse or substance dependence, were treated in a 12-month prospective, open-label trial of olanzapine. Patients were evaluated with multiple efficacy and safety measures at baseline and then monthly thereafter. Statistically significant improvement was noted in psychopathology, levels of hope, and safety measures. Seventy percent (n = 21) of the patients achieved early full substance abuse remission at the end of the study period, while 30% (n = 9) achieved early partial substance abuse remission. Our results indicate that olanzapine treatment improved psychopathology, increased hopefulness, and reduced antipsychotic-associated side effects. The benefits observed with olanzapine treatment may contribute to the patients' substance abuse remission.
Assuntos
Antipsicóticos/uso terapêutico , Pirenzepina/análogos & derivados , Pirenzepina/uso terapêutico , Esquizofrenia/tratamento farmacológico , Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico , Adulto , Análise de Variância , Benzodiazepinas , Feminino , Humanos , Masculino , Olanzapina , Estudos Prospectivos , Resultado do TratamentoAssuntos
Antipsicóticos/uso terapêutico , Pirenzepina/análogos & derivados , Complicações na Gravidez/tratamento farmacológico , Esquizofrenia/tratamento farmacológico , Antipsicóticos/efeitos adversos , Benzodiazepinas , Feminino , Humanos , Olanzapina , Pirenzepina/efeitos adversos , Pirenzepina/uso terapêutico , Gravidez , Resultado da GravidezRESUMO
BACKGROUND: Clozapine is an atypical antipsychotic indicated for the management of severely ill patients with schizophrenia who have failed to respond adequately to standard drug treatment. The significant risk of agranulocytosis and seizure associated with clozapine has led to the restrictions in its use. Additionally, drug-induced sedation, sialorrhea, enuresis, and weight gain are often cited as problematic consequences of clozapine treatment. Our primary objective was to determine the effectiveness and safety of a method of slow cross-titration from clozapine to olanzapine among patients responsive to clozapine treatment but experiencing medication-induced adverse events. METHOD: Changes in symptomatology, mood, subjective response, and safety were examined in 20 outpatients meeting DSM-IV criteria for schizophrenia or schizoaffective disorder who converted from clozapine to olanzapine. Patients were considered clozapine-responsive as evidenced by improved social function and decreased symptoms with clozapine therapy; however, they were interested in alternative pharmacologic treatment because of clozapine-related side effects. RESULTS: Equivalent efficacy of olanzapine to clozapine was found in 90% of the patients (18/20) in the study group, without rehospitalization or suicidal behavior in any of the patients. Also notable was a reduction in drug-induced side effects and improved subjective response to pharmacotherapy. CONCLUSION: The successful conversion from clozapine to olanzapine has the potential to provide great benefits for the patient, including reducing drug-induced side effects while maintaining symptom control. These preliminary results suggest that further research on converting clozapine responders to olanzapine is warranted.
Assuntos
Antipsicóticos/uso terapêutico , Clozapina/uso terapêutico , Pirenzepina/análogos & derivados , Pirenzepina/uso terapêutico , Transtornos Psicóticos/tratamento farmacológico , Esquizofrenia/tratamento farmacológico , Adolescente , Adulto , Idoso , Assistência Ambulatorial , Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos , Benzodiazepinas , Clozapina/administração & dosagem , Clozapina/efeitos adversos , Esquema de Medicação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Olanzapina , Pirenzepina/administração & dosagem , Pirenzepina/efeitos adversos , Transtornos Psicóticos/psicologia , Psicologia do Esquizofrênico , Resultado do TratamentoRESUMO
Links between violence, aggression, and mental illness are well documented. Despite this association, our current understanding of the causation and optimal treatment of aggression remains limited. This lack of knowledge is alarming because nurses treating patients with mentally illness are frequent targets of patient aggression. Consequently, the aim of this article is to provide contemporary information regarding the concept of patient aggression, assessment of violent behavior, and implementation of treatment interventions. A review of pharmacological and psychosocial strategies are presented as well. These findings provide psychiatric nurses with a conceptual model as well as practical interventions for patient aggression.
Assuntos
Agressão , Transtornos Mentais/enfermagem , Transtornos Mentais/terapia , Avaliação em Enfermagem , Enfermagem Psiquiátrica , Violência , Georgia , Humanos , Transtornos Mentais/psicologia , Enfermagem Psiquiátrica/métodos , Fatores de Risco , Estados UnidosAssuntos
Antipsicóticos/uso terapêutico , Discinesia Induzida por Medicamentos/prevenção & controle , Pirenzepina/análogos & derivados , Esquizofrenia/tratamento farmacológico , Adulto , Antipsicóticos/efeitos adversos , Benzodiazepinas , Discinesia Induzida por Medicamentos/epidemiologia , Discinesia Induzida por Medicamentos/etiologia , Humanos , Masculino , Olanzapina , Exame Físico , Pirenzepina/efeitos adversos , Pirenzepina/uso terapêuticoAssuntos
Antipsicóticos/uso terapêutico , Ingestão de Líquidos/efeitos dos fármacos , Hiponatremia/tratamento farmacológico , Pirenzepina/análogos & derivados , Esquizofrenia Paranoide/tratamento farmacológico , Adulto , Benzodiazepinas , Feminino , Humanos , Hiponatremia/etiologia , Olanzapina , Pirenzepina/uso terapêutico , Escalas de Graduação Psiquiátrica , Esquizofrenia Paranoide/sangue , Esquizofrenia Paranoide/psicologia , Psicologia do Esquizofrênico , Sódio/sangueAssuntos
Anticonvulsivantes/uso terapêutico , Clozapina/efeitos adversos , Epilepsia/induzido quimicamente , Esquizofrenia/tratamento farmacológico , Anticonvulsivantes/efeitos adversos , Clozapina/uso terapêutico , Interações Medicamentosas , Eletroencefalografia/efeitos dos fármacos , Epilepsia/tratamento farmacológico , HumanosRESUMO
OBJECTIVE: The authors' aim was to assess the safety and efficacy of starting clozapine in a structured, long-term, partial hospitalization program that included protocols for detecting and managing side effects and adverse reactions to the drug as well as therapeutic programming to enhance patients' reintegration into community life. METHODS: Medical records of 47 patients with schizophrenia or schizoaffective disorder who were started on clozapine in the partial hospitalization program were analyzed. Data on incidence and management of adverse reactions, number of hospitalizations, status of symptoms, and changes in patients' social functioning for periods up to 12 months after initiation of clozapine were collected. RESULTS: Although adverse reactions were common in the first weeks of treatment, they were managed with dosing strategies, monitoring, and concomitant medication so that no patient had to discontinue the medication. Psychotic symptoms and symptoms of tardive dyskinesia decreased significantly during the study period. At 12-month follow-up, most patients were able to attend school, hold paying or volunteer jobs, and live independently. CONCLUSIONS: Clozapine can be safely initiated outside an inpatient setting. Partial hospitalization programs can enhance patients' reintegration into the community through a combination of treatment with clozapine and rehabilitative and psychotherapeutic programming.